Advertisement

Chemokine und Chemokinrezeptoren: Bedeutung in der Dermatologie

  • Michael Sticherling
Conference paper
  • 12 Downloads
Part of the Fortschritte der praktischen Dermatologie und Venerologie book series (DERMATOLOGIE, volume 18)

Zusammenfassung

Die geregelte Kommunikation von Zellen unter physiologischen und pathologischen Bedingungen wird durch ein Netzwerk verschiedener zellständiger und sezernierter Mediatoren vermittelt. Untersuchungen der letzten zwei Jahrzehnte haben in diesem Zusammenhang eine neuartige Gruppe von Peptiden charakterisiert, die aufgrund ihrer biochemischen und funktionellen Verwandtschaft inzwischen als Chemokine fest etabliert sind [2,4,6,16,36]. Der Name leitet sich aus der ursprünglich im Zentrum der Untersuchungen stehenden biologischen Aktivität zahlreicher Mitglieder dieser Familie ab. Als Chemotaxis wird dabei das Phänomen der gerichteten Wanderung von Zellen auf einen löslichen Mediatorgradienten hin definiert, im Gegensatz zu Haptotaxis, bei der sich ein festphasengebundener Gradient findet. Zahlreiche chemisch sehr unterschiedliche Proteine und Lipide zeigen chemotaktische Aktivität und sind sowohl endogenen als auch exogenen Ursprungs. Exemplarisch seien das Komplementspaltprodukt C5a und Leukotrien B4 (LTB4) als endogene und Lipopolysaccharid (LPS) und verschiedene andere bakterielle Proteine als exogene Mediatoren genannt [25]

Literatur

  1. 1.
    Albanesi C, Scarponi C, Sebastiani S, Cavani A, Federici M, Sozzani S, Girolomoni G (2001) A cytokine-to-chemokine axis between T lymphocytes and keratinocytes can favor Thl cell accumulation in chronic inflammatory skin diseases. J Leukoc Biol 70: 617–623PubMedGoogle Scholar
  2. 2.
    Baggiolini M (2001) Chemokines in pathology and medicine. J Intern Med 250: 91–104PubMedCrossRefGoogle Scholar
  3. 3.
    Barcellos LF, Schito AM, Rimmler JB, Vittinghoff E, Shih A, Lincoln R, Callier S, Elkins MK, Goodkin DE, Haines JL, Pericak-Vance MA, Hauser SL, Oksenberg JR (2000) CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51: 281–288PubMedCrossRefGoogle Scholar
  4. 4.
    Christopherson K 2nd, Hromas R (2001) Chemokine regulation of normal and pathologic immune responses. Stem Cells 19: 388–396PubMedCrossRefGoogle Scholar
  5. 5.
    Eisner J, Kapp A (2001) The chemokine network in eosinophil activation. Allerg Asthma Proc 22:139–148CrossRefGoogle Scholar
  6. 6.
    Fernandez EJ, Lolis E (2002) Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol 42: 469–499PubMedCrossRefGoogle Scholar
  7. 7.
    Fiten P, Vandenbroeck K, Dubois B, Van Coillie E, Nelissen I, Van Damme J, Ligers A, Hillert J, Andersson M, Olsson T, Opdenakker G (1999) Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development. J Neuroimmunol 95: 195–201PubMedCrossRefGoogle Scholar
  8. 8.
    Flanagan K, Kaufman HL (2002) Chemokines and cancer. Cancer Invest 20: 825–834PubMedCrossRefGoogle Scholar
  9. 9.
    Geliebter J (2002) Chemokines: small, but powerful regulators of the immune system-potential anti-tumor targets and reagents. Cancer Invest 20: 857 - 858PubMedCrossRefGoogle Scholar
  10. 10.
    Girolomoni G, Sebastiani S, Albanesi C, Cavani A (2001) Tcell subpopulations in the development of atopic and contact allergy. Curr Opin Immunol 13: 733–737PubMedCrossRefGoogle Scholar
  11. 11.
    Gillitzer R (2001) Inflammation in human skin: a model to study chemokine-mediated leukocyte migration in vivo. J Pathol 194: 393–394PubMedCrossRefGoogle Scholar
  12. 12.
    Goebeler M, Trautmann A, Voss A, Brocker EV, Toksoy A, Gillitzer R (2001) Differential and sequential expression of multiple chemokines during elicitation of allergic contact hypersensitivity. Am J Pathol 158: 431–440PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Godessart N, Kunkel SL (2001) Chemokines in autoimmune disease. Curr Opin Immunol 13: 670–675PubMedCrossRefGoogle Scholar
  14. 14.
    Horuk R, Ng HP (2000) Chemokine receptor antagonists. Med Res Rev 20:155–168PubMedCrossRefGoogle Scholar
  15. 15.
    Hub E, Rot A (1998) Binding of RANTES, MCP-1, MCP-3, and MIP-1 alpha to cells in human skin. Am J Pathol 152: 749–757PubMedCentralPubMedGoogle Scholar
  16. 16.
    Luster AD (2002) The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14:129–135PubMedCrossRefGoogle Scholar
  17. 17.
    Luster AD (2001) Antichemokine immunotherapy for allergic diseases. Curr Opin Allergy Clin Immunol 1: 561–567PubMedCrossRefGoogle Scholar
  18. 18.
    McDermott DH, Murphy PM (2000) Chemokines and their receptors in infectious disease. Springer Semin Immunopathol 22: 393–415PubMedCrossRefGoogle Scholar
  19. 19.
    Miller EJ, Cohen AB, Nagao S, Griffith D, Maunder RJ, Martin TR, Wiener-Kronish JP, Sticherling M, Christophers E, Matthay MA (1992) Elevated levels of NAP-l/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am Rev Respir Dis 146: 427–432PubMedCrossRefGoogle Scholar
  20. 20.
    Murphy PM (2001) Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345: 833–835PubMedCrossRefGoogle Scholar
  21. 21.
    Payne AS, Cornelius LA (2002) The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatoll 18: 915–922CrossRefGoogle Scholar
  22. 22.
    Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2:106–115PubMedCrossRefGoogle Scholar
  23. 23.
    Rennekampff HO, Hansbrough JF, Kiessig V, Dore C, Sticherling M, Schröder JM (2000) Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res 93: 41–54PubMedCrossRefGoogle Scholar
  24. 24.
    Schmuth M, Neyer S, Rainer C, Grassegger A, Fritsch P, Romani N, Heufler C (2002) Expression of the C-C chemokine MIP-3alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 11:135–142PubMedCrossRefGoogle Scholar
  25. 25.
    Schröder JM, Christophers E (1986) Identification of C5a des arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 87: 53 - 58PubMedCrossRefGoogle Scholar
  26. 26.
    Schröder JM, Noso N, Sticherling M, Christophers E (1996) Role of eosinophil-chemotactic C-C-chemokines in cutaneous inflammation. J Leukocyte Biol 59:1–5PubMedGoogle Scholar
  27. 27.
    Schroppel B, Fischereder M, Ashkar R, Lin M, Kramer BK, Mardera B, Schiano T, Murphy B (2002) The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2: 640–645PubMedCrossRefGoogle Scholar
  28. 28.
    Schwarz MK, Wells TN (2002) New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 1: 347–358PubMedCrossRefGoogle Scholar
  29. 29.
    Sebastiani S, Albanesi C, De PO, Puddu P, Cavani A, Girolomoni G (2002) The role of chemokines in allergic contact dermatitis. Arch Dermatol Res 293: 552–559PubMedCrossRefGoogle Scholar
  30. 30.
    Sebastiani S, Albanesi C, Nasorri F, Girolomoni G, Cavani A (2002) Nickel-specific CD4(+) and CD8(+) T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis. J Invest Dermatol 118: 1052–1058PubMedCrossRefGoogle Scholar
  31. 31.
    Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P (2000) CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102: 98–106PubMedCrossRefGoogle Scholar
  32. 32.
    Sticherling M, Bornscheuer E, Schröder JM, Christophers E (1991) Localization of NAP-l/IL-8 immunoreactivity in normal and psoriatic skin. J Invest Dermatol 96: 26 - 30PubMedCrossRefGoogle Scholar
  33. 33.
    Sticherling M, Sautier W, Schröder JM, Christophers E (1999) Interleukin 8 plays its role at local level in psoriasis vulgaris. Acta Dermato Venereol (Stockh) 79:4–8CrossRefGoogle Scholar
  34. 34.
    Sticherling M., Baisch C, Bornscheuer E, Christophers E, Schröder JM (2002) The role of the Duffy antigen-related chemokine receptor in psoriasis vulgaris. Cytokine 18: 329–333PubMedCrossRefGoogle Scholar
  35. 35.
    Tanaka Y, Kimata K, Adams DH, Eto S (1998) Modulation of cytokine function by heparan sulfate proteoglycans: sophisticated models for the regulation of cellular responses to cytokines. Proc Assoc Am Physicians 110:118–125PubMedGoogle Scholar
  36. 36.
    Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Michael Sticherling

There are no affiliations available

Personalised recommendations